Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04302025
Title A Study of Alectinib, Entrectinib, Vemurafenib Plus Cobimetinib, or Pralsetinib in Patients With Resectable Stages II-III Non-Small Cell Lung Cancer With ALK, ROS1, NTRK, BRAF V600, or RET Molecular Alterations
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Genentech, Inc.
Indications

lung non-small cell carcinoma

Therapies

Cobimetinib + Vemurafenib

Entrectinib

Alectinib

Pralsetinib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST